Skip to main content
. 2020 Nov 26;24:92–103. doi: 10.1016/j.omtn.2020.11.019

Figure 3.

Figure 3

miR-27a accelerates angiogenesis of HUVECs by downregulating SFRP1 expression

(A) CCK-8 assay for cell viability in HUVECs transfected with miR-27a mimic (M.miR-27a), miR-27a inhibitor (I.miR-27a), siRNA targeting SFRP1 (siSFRP1), SFRP1 overexpression (oe-SFRP1), and miR-27a mimic NC (M.NC), miR-27a inhibitor NC (I.NC), siRNA NC (siNC), and control. (B) Transwell assay for cell migration ability in HUVECs transfected with M.miR-27a, I.miR-27a, siSFRP1, oe-SFRP1, and M.NC, I.NC, siNC, and control. (C) Matrigel tubule formation assay for capillary-like tubes in HUVECs transfected with M.miR-27a, I.miR-27a, siSFRP1, oe-SFRP1, and M.NC, I.NC, siNC, and control. (D) Western blot assay of angiogenesis factors VEGF and TNF-α in HUVECs transfected with M.miR-27a, I.miR-27a, siSFRP1, oe-SFRP1, and M.NC, I.NC, siNC, and control, normalized to β-actin. (E) CCK-8 assay for cell viability in HUVECs transfected with M.NC, M.miR-27a, M.miR-27a + control, and M.miR-27a + oe-SFRP1. (F) Transwell assay for cell migration ability in HUVECs transfected with M.NC, M.miR-27a, M.miR-27a + control, and M.miR-27a + oe-SFRP1. (G) Matrigel tubule formation assay for capillary-like tubes in HUVECs transfected with M.NC, M.miR-27a, M.miR-27a + control, and M.miR-27a + oe-SFRP1. (H) Western blot assay for angiogenesis-related factors VEGF and TNF-α in HUVECs transfected with M.NC, M.miR-27a, M.miR-27a + control, and M.miR-27a + oe-SFRP1, normalized to β-actin. ∗p < 0.05 versus siNC group, #p < 0.05 versus control group, &p < 0.05 versus M.NC group, $p < 0.05 versus I.NC group or M.miR-27a + control group. The measurement data are summarized by mean ± SD. The comparison among multiple groups was analyzed by one-way ANOVA with Tukey’s post hoc test. Statistical analysis in relation to time-based measurements was realized using two-way ANOVA, followed by a Bonferroni’s post hoc test. Cellular experiment was repeated three times.